Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases

Contributed by: PR Newswire

Tags

Healome-Therapeutics

More Like This

Healx Strengthens Focus on Preventing Cancer Recurrence by Leveraging Its AI-Powered Platform and Advancing Its Oncology Pipeline Through a Strategic Transaction with Vuja De Sciences

PR Newswire associated0

Berlin Heals Successfully Raises Over 10M USD to Expand the New Less Invasive Approach to More Heart Failure Patients

Group photo management AOP Health and RHEACELL, from left to right: Dr. Christoph Ganss, Dr. Andreas Kluth, RHEACELL Dr. Rudolph Widmann, Dr. Günther Krumpl, Dr. Martin Steinhart, Bernhard Nachbaur, LL.M., AOP Health

RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds

Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

PR Newswire associated0

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

PR Newswire associated0

Berlin Heals Holding AG Successfully Raises Over 5Million USD Round for Advancing New Less Invasive Approaches

Healthera secures £2m strategic investment to accelerate digital pharmacy platform growth and North American expansion

Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference